

MEDICAL ASSISTANCE BULLETIN

ISSUE DATE

July 29, 2021

EFFECTIVE DATE

April 1, 2021

NUMBER

01-21-08, 05-21-03, 08-21-09, 09-21-07, 24-21-07, 26-21-02, 30-21-04, 31-21-09, 33-21-08

SUBJECT

Expansion of Providers for the Administration of SARS-CoV-2 Vaccines and Monoclonal Antibody Therapy

ВΥ

Sally A. Kozak, Deputy Secretary

Office of Medical Assistance Programs

ally h. Kozel

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that the Department of Human Services (Department) is expanding the scope of MA enrolled providers who may bill the MA Program for administration of the novel coronavirus (SARS-CoV-2) vaccines and monoclonal antibody therapy.

SCOPE:

This bulletin applies to physicians, certified registered nurse practitioners, certified nurse midwives, outpatient hospital clinics, independent medical/surgical clinics, home health agencies, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, partial psychiatric hospitals, ambulance providers and licensed pharmacies enrolled in the MA Program who may administer SARS-CoV-2 vaccines and/or monoclonal antibody therapies in the Fee-for-Service (FFS) and managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should contact the appropriate managed care organization with any billing questions.

BACKGROUND:

The Pennsylvania Department of Health (PA DOH) developed a multi-phased vaccination program in response to the coronavirus disease 2019 (COVID-19) pandemic based on guidance from the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services. PA DOH issued a list of persons authorized to

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx.

administer the SARS-CoV-2 vaccines, which is available at: https://www.health.pa.gov/topics/Documents/Programs/Immunizations/Persons%20Authorized %20to%20Administer%20COVID-19%20Vaccinations.pdf.

The MA Program currently pays physicians, certified registered nurse practitioners, certified registered midwives, outpatient hospital-based clinics, independent medical/surgical clinics, and licensed pharmacies for the administration of SARS-CoV-2 vaccines. To support the vaccination of MA beneficiaries, the Department has identified and expanded the scope of MA enrolled providers who may bill for the administration of the SARS-CoV-2 vaccines to include the following provider types: home health agencies, ambulance providers, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, and partial psychiatric hospitals for SARS-CoV-2 vaccines administered by staff who is authorized under state law to administer the vaccine.

The MA Program currently pays physicians, outpatient hospital clinics, and independent medical surgical clinics for the administration of unapproved monoclonal antibody therapies for the treatment of mild to moderate SARS-CoV-2. To support the treatment of MA beneficiaries who have mild to moderate SARS-CoV-2, the Department expanded the list of providers who may bill for the administration of SARS-CoV-2 monoclonal antibody therapy to include renal dialysis centers.

DISCUSSION:

Since December 2020, the Department has issued several MA bulletins (MABs) to announce the addition of procedure codes to the MA Program Fee Schedule for the administration of SARS-CoV-2 vaccines to MA beneficiaries. Providers should refer to the following MABs when billing for the administration of SARS-CoV-2 vaccines.

- MAB 01-20-59, "Addition to the Medical Assistance Program Fee Schedule for Administration of SARS-CoV-2 Vaccines"
- MAB 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists"
- MAB 01-20-62, "SARS-CoV-2 Vaccine Updates"
- MAB 01-21-01, "Administration of SARS-CoV-2 Vaccine Manufactured by Janssen Biotech, Inc."
- MAB 01-21-03, "Fee Increase for the Administration of SARS-CoV-2 Vaccines"

Since March 2021, the Department has issued two MABs to announce the addition of procedure codes to the MA Program Fee Schedule for the administration of unapproved monoclonal antibody therapies for the treatment of MA beneficiaries who have mild to moderate SARS-CoV-2. Providers should refer to the following MABs when billing for the administration of monoclonal antibody therapies.

- MAB 01-21-02, "Updates to the Medical Assistance Program Fee Schedule for Administration of SARS-CoV-2 Monoclonal Antibody Therapy"
- MAB 01-20-61, "Addition to the Medical Assistance Program Fee Schedule for Administration of SARS-CoV-2 Monoclonal Antibody Therapy"

The administration of SARS-CoV-2 monoclonal antibody therapy to MA beneficiaries by renal dialysis centers can be billed for dates of service on and after the dates that the Emergency Use Authorizations (EUA) were granted by the U.S. Food and Drug Administration (FDA) for CPT codes M0239, M0243, and M0245. CPT code M0239 can only be billed until April 16, 2021, which is the date the FDA revoked the EUA for the monoclonal antibody therapy associated with this CPT code.

The MABs referenced above are available on the Department's website at: https://www.dhs.pa.gov/docs/For-Providers/Pages/Bulletin-Search.aspx.

PROCEDURE:

MA providers, other than pharmacies, in both the FFS and managed care delivery systems are to bill for the administration of the SARS-CoV-2 vaccines using the applicable CPT codes. MA enrolled pharmacies in the managed care delivery system should contact the managed care organization for information on billing for the administration of the SARS-CoV-2 vaccine.

Attachment A, "Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Vaccines" identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee with effective dates for the procedure codes for providers submitting MA FFS claims for the administration of SARS-CoV-2 vaccines.

MA providers in the FFS delivery system who may administer monoclonal antibody therapies are to bill for the administration of monoclonal antibody therapies using the applicable CPT codes. MA providers in the managed care delivery system who may administer monoclonal antibody therapies should contact the managed care organization for information on billing for monoclonal antibody therapies administered to MA beneficiaries.

Attachment B, "Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Monoclonal Antibody Product" identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee with effective dates for the procedure codes for providers submitting MA FFS claims for the administration of SARS-CoV-2 monoclonal antibody therapies. Additional billing information can be found in both MAB 01-21-02 and MAB 01-20-61.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MAF ee-Schedule aspx.

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code and the units dispensed for the vaccine. Providers may access the online version of the MA Drug Fee Schedule on the Department's website at:

https://www.dhs.pa.gov/providers/PharmacyServices/Pages/default.aspx.

Providers may not bill the MA Program for a vaccine or monoclonal antibody therapy they receive at no cost, including SARS-CoV-2 vaccines or therapies purchased by the federal government.

ATTACHMENTS:

Attachment A - Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Vaccines

Attachment B - Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Monoclonal Antibody Product

Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Vaccines

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee prior to 3/14/21	MA Fee on and after 3/15/2021	Prior Authorization Required	Limits
	Immunization administration by intramuscular injection of severe									
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus									
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative									
0001A	free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	01	183	22			\$16.94	\$40.00	No	once per day
							•			
	Immunization administration by intramuscular injection of severe									
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative									
0001A	free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	05	050, 051	12, 99			\$16.94	\$40.00	No	once per day
000271		- 55	030, 031	11)	•		720.31	γ 10.00		
	Immunization administration by intramuscular injection of severe)			
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus									
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative			12, 31, 32, 50,			_			
0001A	free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	08	080	99			\$16.94	\$40.00	No	once per day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus									
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative			12, 31, 32, 72						
0001A	free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	08	081	99			\$16.94	\$40.00	No	once per day
					*					
	Immunization administration by intramuscular injection of severe									
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus	·								
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative						_			
0001A	free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	08	082	49			\$16.94	\$40.00	No	once per day
	Impunitation administration by intra-consular injection of consular									
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus									
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative									
0001A	free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	08	110	11, 49, 99			\$16.94	\$40.00	No	once per day
				, , , = =						, ,
	Immunization administration by intramuscular injection of severe									
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus									
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative						_			
0001A	free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	08	184	57, 99			\$16.94	\$40.00	No	once per day

0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	09	All	11, 12, 31, 32, 99		\$16.94	\$40.00	No	once per day
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	11	110, 127	99		\$16.94	\$40.00	No	once per day
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose		113, 114	52		\$16.94	\$40.00	No	once per day
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose		All	11, 31, 32, 99		\$16.94	\$40.00	No	once per day
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose		260, 261	12, 99		\$16.94	\$40.00	No	once per day
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose		300	12, 65		\$16.94	\$40.00	No	once per day
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose		All	11, 12, 31, 32, 99		\$16.94	\$40.00	No	once per day
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	33	335	11, 12, 99		\$16.94	\$40.00	No	once per day

0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	01	183	22		\$28.39	\$40.00	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	05	050 051	12, 99		\$28.39	\$40.00	No	once nor day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative		050, 051	12, 31, 32, 50,					once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative		080	99 12, 31, 32, 72, 99		\$28.39	\$40.00	No	once per day
0002A 0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	08	081	49		\$28.39	\$40.00	No No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	7	110	11, 49, 99		\$28.39	\$40.00	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose		184	57, 99		\$28.39	\$40.00	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	09	All	11, 12, 31, 32, 99		\$28.39	\$40.00	No	once per day

			1					<u> </u>	
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	11	110, 127	99		\$28.39	\$40.00	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	11	113, 114	52		\$28.39	\$40.00	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	24	All	11 , 31, 3 2 , 99		\$28.39	\$40.00	No	once per day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative								
0002A 0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	26	300	12, 99 12, 65		\$28.39	\$40.00	No No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose		All	11, 12, 31, 32, 99		\$28.39	\$40.00	No	once per day
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose		335	11, 12, 99		\$28.39	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	01	183	22		\$16.94	\$40.00	No	once per day

		1	1	T	<u> </u>	Ι		<u> </u>	ī	
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	05	050, 051	12, 99			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose		080	12, 31, 32, 50, 99			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	08	081	12, 31, 32, 72, 99			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	08	082	49			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	08	110	11, 49, 99	O		\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	08	184	57, 99			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	09	All	11, 1 2, 31, 32, 99			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose		110, 127	99			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	11	113, 114	52			\$16.94	\$40.00	No	once per day
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	24	All	11, 31, 32, 99			\$16.94	\$40.00	No	once per day

mmunization administration by intramuscular injection of severe cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus lisease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ree, 100 mcg/0.5mL dosage; first dose	26	260, 261	12, 99			\$16.94	\$40.00	, No	once per day
-	26	260, 261	12, 99			\$16.94	1 540.00 1	, INO	Office per usy
nmunization administration by intramuscular injection of severe	1								once per day
cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ree, 100 mcg/0.5mL dosage; first dose	30	300	12, 65			\$16.94	\$40.00	No	once per day
mmunization administration by intramuscular injection of severe cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ree, 100 mcg/0.5mL dosage; first dose	31	All	11, 12, 31, 32, 99			\$16.94	\$40.00	No	once per day
mmunization administration by intramuscular injection of severe cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative									once per day
mmunization administration by intramuscular injection of severe cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative	.01			Q					once per day
isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative		050, 051	12, 99			\$28.39	\$40.00	No	once per day
mmunization administration by intramuscular injection of severe cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ree, 100 mcg/0.5mL dosage; second dose	08	080	12, 31, 21, 50, 99			\$28.39	\$40.00	No	once per day
mmunization administration by intramuscular injection of severe cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ree, 100 mcg/0.5mL dosage; second dose	08	081	12, 31, 32, 72, 99			\$28.39	\$40.00	No	once per day
mmunization administration by intramuscular injection of severe cute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus isease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ree, 100 mcg/0.5mL dosage; second dose	08	082	49			\$28.39	\$40.00	No	once per day
m clister m clister m clister m clister m clister	inmunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative see, 100 mcg/0.5mL dosage; first dose munization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative see, 100 mcg/0.5mL dosage; first dose munization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative see, 100 mcg/0.5mL dosage; second dose munization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative see, 100 mcg/0.5mL dosage; second dose munization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative see, 100 mcg/0.5mL dosage; second dose munization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative sease [COVID-19]) vaccine, mRNA-LNP, s	amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; first dose amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; first dose amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; second dose amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; second dose amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; second dose amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; second dose amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; second dose	imunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus seases (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; first dose 31 All amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ete, 100 mcg/0.5mL dosage; first dose 33 335 335 336 337 338 339 339 339 339 330 331 331 331	inmunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative 2 p. 100 mcg/0.5mL dosage; first dose 31 All 99 31 All 99 32 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative 2 p. 100 mcg/0.5mL dosage; first dose 33 335 11, 12, 99 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative 2 p. 100 mcg/0.5mL dosage; second dose 183 22 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative 2 p. 100 mcg/0.5mL dosage; second dose 12, 99 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative 2 p. 100 mcg/0.5mL dosage; second dose 12, 31, 21, 50, 99 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus 2 p. 100 mcg/0.5mL dosage; second dose 08 080 99 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus 2 p. 100 mcg/0.5mL dosage; second dose 08 081 99 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus 2 p. 100 mcg/0.5mL dosage; second dose 08 081 99 ammunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus 2 p. 100 mcg/0.5mL dosage; second dose 08 081 99 ammunization administration by intramuscular injection of severe ute respiratory syndrom	immunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative e.e., 100 mcg/0.5mL dosage; first dose 31 All 99 Immunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative e.e., 100 mcg/0.5mL dosage; first dose 33 335 11, 12, 99 Immunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative e.e., 100 mcg/0.5mL dosage; second dose 12 31, 21, 50, 25 Immunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative e.e., 100 mcg/0.5mL dosage; second dose 12 31, 21, 50, 25 Immunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative e.e., 100 mcg/0.5mL dosage; second dose 12 31, 21, 50, 25 33 335 11, 12, 29 24 22 25 25 26 27 26 27 26 27 27 27 27 27 27 27 27 27 27 27 27 27	imunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ee, 100 mcg/0.5mL dosage; first dose 31 All 99 amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ee, 100 mcg/0.5mL dosage; first dose 33 335 11, 12, 99 amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ee, 100 mcg/0.5mL dosage; second dose 41 183 22 amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ee, 100 mcg/0.5mL dosage; second dose 45 050, 051 12, 99 amunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) va	imunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative see, 100 mcg/0.5mL dosage; first dose 31 All 99 \$516.94 32 All 99 \$516.94 33 All 99 \$516.94 34 All 99 \$516.94 35 All 99 \$516.94 36 All 99 \$516.94 37 All 99 \$516.94 38 All 99 \$516.94 39 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 31 All 99 \$516.94 32 All 99 \$516.94 33 All 99 \$516.94 34 All 99 \$516.94 35 All 99 \$516.94 36 All 99 \$516.94 37 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 39 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 31 All 99 \$516.94 32 All 99 \$516.94 33 All 99 \$516.94 34 All 99 \$516.94 35 All 99 \$516.94 36 All 99 \$516.94 37 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 39 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 31 All 99 \$516.94 32 All 99 \$516.94 33 All 99 \$516.94 34 All 99 \$516.94 35 All 99 \$516.94 36 All 99 \$516.94 37 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 39 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 31 All 99 \$516.94 31 All 99 \$516.94 31 All 99 \$516.94 31 All 99 \$516.94 32 All 99 \$516.94 33 All 99 \$516.94 34 All 99 \$516.94 35 All 99 \$516.94 36 All 99 \$516.94 37 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 39 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 31 All 99 \$516.94 31 All 99 \$516.94 32 All 99 \$516.94 33 All 99 \$516.94 34 All 99 \$516.94 35 All 99 \$516.94 36 All 99 \$516.94 37 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 39 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 31 All 99 \$516.94 31 All 99 \$516.94 31 All 99 \$516.94 32 All 99 \$516.94 33 All 99 \$516.94 34 All 99 \$516.94 35 All 99 \$516.94 36 All 99 \$516.94 37 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 38 All 99 \$516.94 39 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94 30 All 99 \$516.94	immunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus eases (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine, mRNA-LNP, spike protein, preservative exploratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus sease (COVID-19)) vaccine,	imunization administration by intramuscular injection of severe ute respiratory syndrome coronavirus 2 (\$ARS-CoV-2) (Coronavirus assase (COVD-19)) vaccine, mRNA-LNP, spike protein, preservative e.p. 100 mrg/D-Nuccine, mRNA-LNP, spike protein, preservative e.p. 100 mrg/D-SmL dosage; first dose 11, 12, 31, 32, 33 11, 12, 39 11, 12, 31, 32 335 11, 12, 39 \$16, 94 \$40.00 No No No No No No No No No

	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus							N	
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	08	110	11, 49, 99		\$28.39	\$40.00	No	once per day
0012A	ince, 100 meg/0.5me dosage, second dose	- 00	110	11, 43, 33		\$20.33	Ş40.00	INO	once per day
	Immunization administration by intramuscular injection of severe								
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative								
	free, 100 mcg/0.5mL dosage; second dose	08	184	57, 99		\$28.39	\$40.00	No	once per day
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus								
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative			11, 12, 31, 32,					
	free, 100 mcg/0.5mL dosage; second dose	09	All	99		\$28.39	\$40.00	No	once per day
					1				
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus					!			
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative								
0012A	free, 100 mcg/0.5mL dosage; second dose	11	110, 127	99		\$28.39	\$40.00	No	once per day
					X				
	Immunization administration by intramuscular injection of severe								
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus								
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative								
0012A	free, 100 mcg/0.5mL dosage; second dose	11	113, 114	52		\$28.39	\$40.00	No	once per day
	Immunization administration by intramuscular injection of severe								
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus								
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative								
0012A	free, 100 mcg/0.5mL dosage; second dose	24	All	11, 31, 32, 99		\$28.39	\$40.00	No	once per day
	Immunization administration by intramuscular injection of severe								
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus								
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative								
0012A	free, 100 mcg/0.5mL dosage; second dose	26	260, 261	12, 99		\$28.39	\$40.00	No	once per day
	Immunization administration by intramuscular injection of severe								
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus								
	disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose								
		30	300	12, 65		\$28.39	\$40.00	No	once per day

22424	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative			11, 12, 31, 32,			420.20	440.00		
0012A	free, 100 mcg/0.5mL dosage; second dose	31	All	99			\$28.39	\$40.00	No	once per day
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	33	335	11, 12, 99			\$28.39	\$40.00	No	once per day
								_		
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage,		100)	400.00	410.00		
0031A	single dose Immunization administration by intramuscular injection of severe	01	183	22			\$28.39	\$40.00	No	once per day
	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage,									
0031A	single dose Immunization administration by intramuscular injection of severe	05	050, 051	12, 99			\$28.39	\$40.00	No	once per day
0031A	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		080	12, 31, 32, 50, 99	X		\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		081	12, 31, 32, 72, 99			\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		082	49			\$28.39	\$40.00	No	once per day
00214	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dosa		110	11 40 00			¢29.20	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage,		110	11, 49, 99			\$28.39	\$40.00	No	once per day
0031A	single dose	08	184	57, 99			\$28.39	\$40.00	No	once per day

	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage,			11, 12, 31, 32,				N	
0031A	single dose	09	All	99		\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		110, 127	99		\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		113, 114	52		\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		All	11, 31, 32, 99		\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		260, 261	12, 99		\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		300	12, 65		\$28.39	\$40.00	No	once per day
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		All	11, 12, 31, 32, 99		\$28.39	\$40.00	No	once per day
00214	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose		225	11 12 00		¢20 20	\$40.00	No	once per day
0031A	single dose	33	335	11, 12, 99	<u> </u>	\$28.39	\$40.00	No	once per day

Updates to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of SARS-CoV-2 Monoclonal Antibody Product

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	Effective Date	End Date	MA Fee	Prior Authorization Required	Limits
M0239	Intravenous infusion, bamlanivimab- xxxx, includes infusion and post administration monitoring	01	017	23			11/10/2020	4/16/2021	\$247.68	No	once per day
	Intravenous infusion, bamlanivimab- xxxx, includes infusion and post administration monitoring	01	183	22			11/10/2020	4/16/2021	\$247.68	No	once per day
M0239	Intravenous infusion, bamlanivimab- xxxx, includes infusion and post administration monitoring	08	082	49	<		11/10/2020	4/16/2021	\$247.68	No	once per day
M0239	Intravenous infusion, bamlanivimab- xxxx, includes infusion and post administration monitoring	30	300	65			11/10/2020	4/16/2021	\$247.68	No	once per day
	Intravenous infusion, bamlanivimab- xxxx, includes infusion and post administration monitoring	31	All	11, 23, 31, 32, 99			11/10/2020	4/16/2021	\$247.68	No	once per day
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring		017	23	-		11/21/2020	N/A	\$247.68	No	once per day
IVIU243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	01	183	22	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		11/21/2020	N/A	\$247.68	No	once per day
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring		082	49			11/21/2020	N/A	\$247.68	No	once per day
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring		300	65			11/21/2020	N/A	\$247.68	No	once per day

M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	31	All	11, 23, 31, 32, 99		11/21/2020	N/A	\$247.68	No	once per day
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	01	017	23		2/9/2021	N/A	\$247.68	No	once per day
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	01	183	22		2/9/2021	N/A	\$247.68	No	once per day
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	08	082	49		2/9/2021	N/A	\$247.68	No	once per day
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	30	300	65		2/9/2021	N/A	\$247.68	No	once per day
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	31	All	11, 23, 31, 32, 99		2/9/2021	N/A	\$247.68	No	once per day